Latest Breaking News On - Mesoblast the company - Page 1 : comparemela.com

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiEric rosePaul hughesCorporate communications investorsMesoblast limited nasdaqAustralian securities exchangeMesoblast the companyColumbia university department of surgerySuccessfully completes placementAccelerated entitlementEntitlement offerChief medical officerColumbia universityPrincipal investigatorMesoblast limited

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSteve dabkowskiPaul hughesSilviu itescuPharmaceuticals coCorporate communications investorsMesoblast limited nasdaqDrug administrationResearch developmentMarrow transplant clinical trials networkNational institutes of healthAustralian securities exchangeMesoblast the companyChief executive silviu itescuUnited states food

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiSilviu itescuPaul hughesMesoblast limited nasdaqMesoblast the companyAustralian securities exchangeDrug administrationDrug designation programCorporate communications investorsJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiSilviu itescuPaul hughesDrug administrationCorporate communications investorsAustralian securities exchangeMesoblast the companyDrug designation programMesoblast limited nasdaqJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

FDA GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE.

United statesSilviu itescuSteve dabkowskiPaul hughesMesoblast limited nasdaqDrug administrationJournal of the american college cardiologyCorporate communications investorsAustralian securities exchangeRevascor increases size of left heart chamberMesoblast the companyLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery